Related Experiment Video

Updated: Jul 5, 2026

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death
09:18

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death

Published on: December 27, 2016

Prevention of sudden death using beta-blockers. Review of possible contributory actions

G Olsson1, L Rydén

  • 1Department of Medicine, Karolinska Institutet, Danderyd Hospital, Sweden.

Circulation
|December 1, 1991
PubMed

Insights

Beta-blockers are the only proven treatment to reduce sudden death risk in hypertension and post-myocardial infarction patients. Their antifibrillatory effects, alongside other mechanisms, contribute to this significant benefit.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Research

Background:

  • Hypertension is a major risk factor for coronary artery disease (CAD).
  • Sudden death is a primary cause of mortality in patients with hypertension and post-myocardial infarction (MI).
  • Effective treatment strategies must focus on reducing the risk of sudden cardiac death.

Purpose of the Study:

  • To review the various effects of beta-blockers.
  • To discuss how these effects contribute to reducing sudden death risk.
  • To compare the efficacy of beta-blockers with other pharmacological interventions.

Main Methods:

  • Review of clinical studies and animal experimental data on beta-adrenoceptor antagonists.
  • Analysis of pharmacological interventions tested for reducing sudden death risk.
  • Discussion of the antifibrillatory and other potential mechanisms of beta-blockade.

Main Results:

  • Beta-adrenoceptor antagonists are the only pharmacological agents proven effective in reducing sudden death risk.
  • Beta-blockade demonstrates an antifibrillatory effect, particularly relevant for ventricular fibrillation-induced sudden cardiac deaths.
  • The beneficial effects of beta-blockers are likely due to a summation of multiple actions, not solely anti-ischemic or antiarrhythmic effects.

Conclusions:

  • Beta-blocker therapy is crucial for managing hypertension and reducing mortality in post-MI patients.
  • The multifaceted actions of beta-blockers, including antifibrillatory effects, are key to preventing sudden cardiac death.
  • Drugs with limited mechanisms of action have not achieved similar reductions in sudden death risk.

More Related Videos

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke11:32

Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke

Published on: January 3, 2025

Related Concept Videos

Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Prevention of Further Absorption of Poison01:14

Prevention of Further Absorption of Poison

In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...